Cargando…

ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial

Background: Over 13,000 new cases of non-Hodgkin’s lymphoma (NHL) are diagnosed in the UK, with approximately 4,900 attributable deaths each year. Diffuse Large B-cell Lymphoma (DLBCL) is the most common NHL comprising one third of adult NHL cases. R-CHOP (rituximab, cyclophosphamide, doxorubicin, v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, Andrew, Barrans, Sharon, Burton, Cathy, Mercer, Katy, Caddy, Joshua, Chinnery, Fay, Day, Laura, Fernando, Diana, Ardeshna, Kirit, Collins, Graham, Radford, John, Rule, Simon, McMillan, Andrew, Johnson, Peter, Griffiths, Gareth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000 Research Limited 2020
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551525/ https://www.ncbi.nlm.nih.gov/pubmed/33093947 http://dx.doi.org/10.12688/f1000research.22318.1

Ejemplares similares

Multi‐drug Combination Therapy with Vincristine‐Melphalan‐Cyclophosphamide‐Prednisolone Was More Effective than Cyclophosphamide‐Prednisolone in Stage III Myeloma
por: Shimizu, Kazuyuki, et al.
Publicado: (1990)

Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
por: Hornberger, John, et al.
Publicado: (2008)

Dose-intense weekly cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisolone (CMFP) in advanced breast cancer.
por: Cebon, J. S., et al.
Publicado: (1990)

Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021)

Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report
por: Hojo, Nobumasa, et al.
Publicado: (2022)

Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy
por: Shanavas, Mohamed, et al.
Publicado: (2021)

Effectiveness and Adverse Events of Cyclophosphamide, Vincristine, and Prednisolone Chemotherapy in Feline Mediastinal Lymphoma Naturally Infected with Feline Leukemia Virus
por: Sunpongsri, Supita, et al.
Publicado: (2022)

Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study
por: Strati, Paolo, et al.
Publicado: (2021)

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
por: Hawkes, Eliza A., et al.
Publicado: (2021)

Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
por: Lim, Kyu-Hyoung, et al.
Publicado: (2010)

Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
por: Horvat, Matej, et al.
Publicado: (2018)

Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
por: Suzuki, Tomotaka, et al.
Publicado: (2021)

Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL
por: Hartert, Keenan T., et al.
Publicado: (2020)

DLBCL 1L—What to Expect beyond R-CHOP?
por: Stegemann, Maike, et al.
Publicado: (2022)

The Elevation of Cardio-Ankle Vascular Index in a Patient With Malignant Lymphoma Treated With a Combination Therapy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone
por: Shimizu, Naomi, et al.
Publicado: (2017)

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for diffuse large B-cell lymphoma in pregnancy may be associated with preterm birth
por: Lee, Eun Ju, et al.
Publicado: (2014)

Serpentine Supravenous Hyperpigmentation in an HIV Patient Receiving R-CHOP for DLBCL
por: Lancman, Guido, et al.
Publicado: (2018)

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
por: Phillips, Elizabeth H., et al.
Publicado: (2020)

Cocktail therapy with prednisolone, vincristine and sirolimus for Kasabach‑Merritt phenomenon in 10 infants
por: Liu, Qianlong, et al.
Publicado: (2022)

Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
por: Song, Guoqi, et al.
Publicado: (2016)

Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis.
por: Sleijfer, S., et al.
Publicado: (1996)

Pulmonary intravascular large B-cell lymphoma successfully treated with rituximab, cyclophosphamide, vincristine, doxorubicin and prednisolone immunochemotherapy: Report of a patient surviving for over 1 year
por: Nishii-Ito, Shizuka, et al.
Publicado: (2016)

Human Herpesvirus 8–Unrelated Primary Effusion Lymphoma–Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone
por: Shin, Junghoon, et al.
Publicado: (2017)

Anemia Is a Novel Predictive Factor for the Onset of Severe Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Patients Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Therapy
por: Saito, Takashi, et al.
Publicado: (2019)

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
por: de Jonge, A. Vera, et al.
Publicado: (2023)

Cyclophosphamide/methylprednisolone/prednisolone: Multiple infections: case report
Publicado: (2021)

Predictive Value of Interim PET/CT in DLBCL Treated with R-CHOP: Meta-Analysis
por: Sun, Na, et al.
Publicado: (2015)

CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance
por: Qiao, Li-Yan, et al.
Publicado: (2021)

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
por: Cherng, Hua-Jay J., et al.
Publicado: (2022)

A Textbook Case of Human T-lymphotropic Virus-1 (HTLV-1)-Induced Adult T-cell Leukemia Treated With Cyclophosphamide, Hydroxydaunorubicin, Oncovin, and Prednisone/Prednisolone (CHOP)
por: Altaf, Faryal, et al.
Publicado: (2023)

MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma
por: Kendall, Jessica, et al.
Publicado: (2022)

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies
por: Ayed, Ayed O., et al.
Publicado: (2018)

Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma
por: Shi, Yuankai, et al.
Publicado: (2015)

Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL
por: Herrmann, Ken, et al.
Publicado: (2014)

CYCLON and NPM1 Cooperate within an Oncogenic Network Predictive of R-CHOP Response in DLBCL
por: Bouroumeau, Antonin, et al.
Publicado: (2021)

Study on influencing factors of anthracycline-induced subclinical cardiotoxicity in DLBCL patients administered (R)-CHOP
por: Dong, Qian, et al.
Publicado: (2022)

Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement
por: Geng, Hongzhi, et al.
Publicado: (2023)

Risk Factors for Early-Onset Peripheral Neuropathy Caused by Vincristine in Patients With a First Administration of R-CHOP or R-CHOP-Like Chemotherapy
por: Okada, Naoto, et al.
Publicado: (2014)

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin’s lymphoma: the evidence of its therapeutic value
por: Ardeshna, Kirit M.
Publicado: (2007)

Cyclophosphamide/prednisolone/rituximab: Nosocomial COVID-19 infection: case report
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rmhcf6fgjn3ch84f7tu3todkl3